Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

 Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

Shots:

  • TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders
  • The focus of the agreement is to develop non-opioid therapies with advancement of mAbs targeting ion channels utilizing TetraExpress technology for the treatment of pain conditions
  • TetraExpress technology is an Ab discovery platform for developing biologics targeting ion channel for autoimmune diseases and pain

Click here to read full press release/ article | Ref: Imbrium Therapeutics | Image: MassBio

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post